Invesco Ltd. increased its position in Amgen Inc. (NASDAQ:AMGN - Free Report) by 7.5% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 3,887,248 shares of the medical research company's stock after purchasing an additional 270,135 shares during the period. Invesco Ltd. owned about 0.72% of Amgen worth $1,013,172,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Bank of Montreal Can increased its holdings in shares of Amgen by 3.5% in the 4th quarter. Bank of Montreal Can now owns 1,344,419 shares of the medical research company's stock valued at $350,409,000 after purchasing an additional 46,030 shares during the period. Bell Asset Management Ltd increased its stake in Amgen by 142.4% in the 4th quarter. Bell Asset Management Ltd now owns 18,743 shares of the medical research company's stock valued at $4,885,000 after buying an additional 11,010 shares during the period. Sumitomo Mitsui Financial Group Inc. lifted its position in Amgen by 7.0% in the 4th quarter. Sumitomo Mitsui Financial Group Inc. now owns 55,868 shares of the medical research company's stock worth $14,561,000 after buying an additional 3,634 shares in the last quarter. Round Hill Asset Management boosted its stake in shares of Amgen by 1.0% during the 4th quarter. Round Hill Asset Management now owns 44,748 shares of the medical research company's stock valued at $11,663,000 after buying an additional 429 shares during the period. Finally, Ritter Daniher Financial Advisory LLC DE grew its holdings in shares of Amgen by 66.2% during the 4th quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock valued at $33,000 after acquiring an additional 51 shares in the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.
Amgen Price Performance
AMGN traded up $4.57 during midday trading on Friday, reaching $285.98. 3,466,932 shares of the company's stock were exchanged, compared to its average volume of 2,777,164. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. The business has a 50-day simple moving average of $304.33 and a two-hundred day simple moving average of $295.27. The firm has a market capitalization of $153.76 billion, a price-to-earnings ratio of 37.88, a price-to-earnings-growth ratio of 2.63 and a beta of 0.59.
Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, beating analysts' consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. As a group, research analysts predict that Amgen Inc. will post 20.62 EPS for the current year.
Amgen Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be given a dividend of $2.38 per share. The ex-dividend date is Friday, May 16th. This represents a $9.52 dividend on an annualized basis and a yield of 3.33%. Amgen's dividend payout ratio (DPR) is presently 126.09%.
Wall Street Analyst Weigh In
Several analysts recently issued reports on the company. Truist Financial cut their price objective on Amgen from $333.00 to $298.00 and set a "hold" rating for the company in a report on Wednesday, January 8th. Morgan Stanley raised their price target on Amgen from $328.00 to $330.00 and gave the stock an "equal weight" rating in a research note on Wednesday. StockNews.com raised Amgen from a "buy" rating to a "strong-buy" rating in a research note on Wednesday. Bank of America raised their price objective on shares of Amgen from $275.00 to $294.00 and gave the company an "underperform" rating in a research report on Wednesday, March 5th. Finally, Citigroup reissued a "neutral" rating on shares of Amgen in a research report on Wednesday, February 5th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $315.22.
Get Our Latest Research Report on Amgen
Insider Transactions at Amgen
In other news, EVP Jonathan P. Graham sold 25,045 shares of the business's stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $293.12, for a total transaction of $7,341,190.40. Following the completion of the transaction, the executive vice president now directly owns 28,987 shares in the company, valued at approximately $8,496,669.44. The trade was a 46.35 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Nancy A. Grygiel sold 1,589 shares of the company's stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total transaction of $483,802.83. Following the completion of the sale, the senior vice president now directly owns 7,210 shares of the company's stock, valued at $2,195,228.70. The trade was a 18.06 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 69,341 shares of company stock worth $20,644,335. Insiders own 0.69% of the company's stock.
Amgen Profile
(
Free Report)
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
See Also
Before you consider Amgen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.
While Amgen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
